Powell L W, George D K, McDonnell S M, Kowdley K V
University of Queensland, Brisbane, Australia.
Ann Intern Med. 1998 Dec 1;129(11):925-31. doi: 10.7326/0003-4819-129-11_part_2-199812011-00002.
If untreated, hemochromatosis can cause serious illness and early death, but the disease is still substantially under-diagnosed. The cornerstone of screening and case detection is the measurement of serum transferrin saturation and the serum ferritin level. Once the diagnosis is suspected, physicians must use serum ferritin levels and hepatic iron stores on liver biopsy specimens to assess patients for the presence of iron overload. Liver biopsy is also used to establish the presence or absence of cirrhosis, which can affect prognosis and management. A DNA-based test for the HFE gene is commercially available, but its place in the diagnosis of hemochromatosis is still being evaluated. Currently, the most useful role for this test is in the detection of hemochromatosis in the family members of patients with a proven case of the disease. It is crucial to diagnose hemochromatosis before hepatic cirrhosis develops because phlebotomy therapy can avert serious chronic disease and can even lead to normal life expectancy.
如果不进行治疗,血色素沉着症会导致严重疾病并过早死亡,但这种疾病的诊断仍严重不足。筛查和病例检测的基石是血清转铁蛋白饱和度和血清铁蛋白水平的测定。一旦怀疑患有该病,医生必须利用血清铁蛋白水平以及肝活检标本中的肝铁含量来评估患者是否存在铁过载。肝活检还用于确定是否存在肝硬化,这会影响预后和治疗。一种基于DNA的HFE基因检测在市场上可以买到,但其在血色素沉着症诊断中的作用仍在评估中。目前,该检测最有用的作用是在确诊病例的患者家庭成员中检测血色素沉着症。在肝硬化发展之前诊断出血色素沉着症至关重要,因为放血疗法可以避免严重的慢性病,甚至可以使预期寿命正常。